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Current data are released electronically on Internet system, and metabolic diseases for human use
for all individual surveys as they become avail- totaled $23.3 billion, a 12.3-percent increase 
able.  Use: http://www.census.gov/mcd/. from $20.8 billion in 2004; pharmaceutical
Individual reports can be accessed by choosing preparations acting on the central nervous
"Current Industrial Reports (CIR)," clicking on system and sense organs for human use totaled
"CIRs by Subsector;" then choose the survey of $25.0 billion, virtually unchanged from 2004;
interest.  Follow the menu to view the PDF file pharmaceutical preparations acting on the cardio-
or to download the worksheet file (XLS format) vascular system for human use totaled $10.2
to your personal computer. billion, also unchanged from 2004; pharmaceu-
tical preparations acting on the respiratory 
These data are also available on Internet system for human use totaled $16.2 billion, a 
through the U.S. Department of Commerce 7.0-percent increase from $15.1 billion in 2004;
and STAT-USA by subscription.  The Internet pharmaceutical preparations acting on the
address is:  www.stat-usa.gov/.  Follow the digestive or genito-urinary system for human
prompts to register.  Also, you may call use totaled $16.8 billion, a 10.0-percent increase
202-482-1986 or 1-800-STAT-USA, for from $15.3 billion in 2004; pharmaceutical
further information. preparations acting on the skin for human use
totaled $3.2 billion, which is a 1.1-percent 
SUMMARY OF FINDINGS decrease from $3.3 billion in 2004; vitamin,
nutrient, and hematinic preparations for 
The total value of shipments for pharmaceutical human use totaled $6.8 billion, a 2.2-percent
preparations in the United States totaled $116.3 increase from $6.7 billion in 2004; pharma-
billion in 2005, a 5.9-percent increase from $109.9 ceutical preparations affecting parasitic and
billion in 2004.  The leading product category infective diseases for human use totaled $11.2
was pharmaceutical preparations acting on the billion, a 3.9-percent increase from $10.8 billion
central nervous system and sense organs for in 2004; and pharmaceutical preparations for
human use, which remained virtually unchanged veterinary use totaled $3.4 billion, a 26.7-percent
from 2004 staying right at $25.0 billion. increase from $2.7 billion in 2004.
The value of shipments for individual product For general CIR information, explanation of
categories in 2005 were:  pharmaceutical general terms and historical note, see the
preparations affecting neoplasm, endocrine appendix.
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Washington, DC 20233-6900 or call Michael Reich, 301-763-5163.
For mail or fax copies of this publication, please contact the Information Services Center, MCD, Washington, DC 20233-6900, or 
call 301-763-4673.
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Table 1.  Value of Product Class Shipments of Pharmaceutical Preparations, Except Biologicals:  2001 to 2005
[In thousands of dollars]     
Product
code Product description 2005 2004 2003 2002 2001
Pharmaceutical preparations................... 116,301,385 109,851,975 107,561,388 100,741,449 90,181,771
3254121100     Pharmaceutical preparations 
      affecting neoplasms, endocrine
      system, and metabolic diseases,
      for human use................................... 23,341,374 20,789,103 20,064,796 17,499,148 14,818,930
3254124100     Pharmaceutical preparations 
      acting on the central nervous 
      system and sense organs, for
      human use......................................... 25,044,005 25,001,154 24,759,304 24,344,732 18,974,834
3254127100     Pharmaceutical preparations 
      acting on the cardiovascular 
      system, for human use...................... 10,245,714 10,223,797 9,670,724 10,338,754 9,798,444
325412A100     Pharmaceutical preparations 
      acting on the respiratory 
      system, for human use...................... 16,215,729 15,148,446 13,757,675 12,504,287 11,691,747
325412D100     Pharmaceutical preparations 
      acting on the digestive or
      genito-urinary system, for
      human use......................................... 16,775,884 15,251,818 15,051,690 13,373,247 12,615,660
325412G100     Pharmaceutical preparations
      acting on the skin, for human
      use..................................................... 3,245,347 3,283,003 3,082,863 2,844,436 2,708,046
325412L100     Vitamin, nutrient, and hematinic
      preparations, for human use............. 6,827,371 r/ 6,683,224 6,876,680 6,028,849 5,883,934
325412P100     Pharmaceutical preparations 
      affecting parasitic and
      infective diseases, for 
      human use......................................... 11,244,039 10,818,532 11,848,410 11,336,918 11,192,713
325412T100     Pharmaceutical preparations
      for veterinary use.............................. 3,361,922 r/ 2,652,898 2,449,246 2,471,078 2,497,463
      r/Revised 5 percent or more from previously published data.
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325412 Pharmaceutical preparations (except
  biologicals)....................................................  116,301,385 97,791,065 14,064,193 4,446,127 109,851,975 92,686,683 13,682,193 r/ 3,483,099
3254121     Pharmaceutical preparations 
      affecting neoplasms, endocrine
      system, and metabolic diseases,
      for human use...........................................  23,341,374 (D) (D) (D) 20,789,103 r/  19,153,296 (D) (D)
        Hormones and synthetic
          substitutes:   
            Corticoids:
3254121111                 Systemic..........................................  437,100 (D) (D) (D) 516,926 (D) (D) (D)
3254121116                 Local and topical, including
                  anti-infective combinations.......... a/ 646,215 (D) (D) - 480,759 470,567 10,192 -
3254121121             Androgens........................................... b/ 88,305 b/ 88,305 - (D) r/ 98,116 r/        98,116 - (D)
3254121126             Estrogens............................................. a/ 660,513 a/ 660,513 - - a/ 656,176 a/      656,176 - -
3254121131             Insulin and antidiabetic 
              agents................................................  1,720,434 1,720,434 - (D) r/ 1,710,664 r/  1,710,664 - (D)
3254121136             ACTH (corticotropin)...........................  - - - - - - - -
3254121141             Oral contraceptive 
              preparations...................................... c/ 473,878 c/ 473,878 - - c/ 473,878 c/     473,878 - -
3254121146             Progestogens (excluding   
              premenstrual tension
              preparations, see 
              code 325412D185)............................  232,047 232,047 - (D) 215,009 215,009 - (D)
3254121151             Sex hormone combinations, 
             (except progestogen combi-
             nations)..............................................  (D) (D) - - (D) (D) - -
3254121156             Thyroid and antithyroid
              preparations, including
              iodides............................................... a/ 891,449 a/ 891,449 - - a/ 1,010,314 a/  1,010,314 - -
3254121161             Anabolic agents................................... b/ 32,246 b/ 32,246 - - b/r/ 17,103 b/r/       17,103 - -
3254121166             Other hormone preparations..............  (D) (D) (D) - (D) (D) (D) -
        Antineoplastic agents:
3254121171             Radioactive isotopes for internal
               use....................................................  (D) (D) - - (D) (D) - -
3254121176             Specific antineoplastic agents............. b/ 3,085,880 b/ 3,085,880 - (D) r/ 2,824,200 r/  2,824,200 - (D)
3254121181         Other pharmaceutical prepara-
          tions affecting neoplasms, the
          endocrine system, and metabolic,   
          for human use.......................................  12,573,633 (D) (D) (D) r/ 10,235,130 (D) (D) (D)
3254124     Pharmaceutical preparations acting
      on the central nervous system and
      the sense organs, for human use..............  25,044,005 a/ 21,530,156 a/ 2,299,898 a/ 1,213,951 25,001,154 r/ 22,385,284 2,127,200 r/   488,670
3254124111         Parasympathomimetic cholinergic
          drugs.....................................................  (D) (D) - (D) 21,500 21,500 - (D)
3254124114         Skeletal muscle relaxants........................  401,896 (D) (D) (D) r/ 406,918 (D) (D) (D)
        Internal analgesics and 
         antipyretics:
           Narcotic:
3254124117                Opium and derivatives..................... a/ 715,514 a/ 715,514 - - 416,943 416,943 - -
3254124121                Synthetic narcotics...........................  1,106,172 1,106,172 - (D) 2,442,416 2,442,416 - (D)
           Nonnarcotic:
               Salicylates:
3254124124                   Aspirin (acetylsalicylic acid).........  (D) - (D) (D) 261,384 (D) (D) (D)
3254124127                   Other salicylates, such as
                    sodium  salicylate …………………  (D) (D) (D) - (D) (D) (D) -
3254124131                Aspirin combinations.......................  147,857 (D) (D) - 136,447 6,505 129,942 -
3254124134                Acetaminophen and 
                 combinations..................................  511,408 a/ 59,701 451,707 12,717 557,132 a/       87,959 469,173 r/    10,046
3254124137                Antiarthritics (nonhormonal)........... a/ 699,638 319,741 379,897 b/ 108,312 r/ 600,458 r/     386,270 214,188 b/    82,096
3254124141         Other internal analgesics and
          antipyretics, including efferves-
          cent types and suppositories …………… a/ 62,064 (D) (D) (D) a/ 66,291 (D) (D) (D)
3254124144         Anticonvulsants (except pheno-
          barbital).................................................  (D) (D) - 23,470 1,430,600 1,430,600 - 20,260
        Psycotherapeutic agents:
3254124147            Antidepressants................................... a/ 5,365,758 5,365,758 - (D) 5,655,281 5,655,281 - 150,793
           Tranquilizers:
3254124151               Phenothiazine derivatives.................  92,192 92,192 - - 115,974 115,974 - -
3254124154               Other tranquilizers............................ c/ 53,916 c/ 53,916 - - 45,789 45,789 - -
3254124157            Other psychotherapeutic agents.......... b/ 4,956,882 b/ 4,956,882 - - 4,509,258 4,509,258 - -
        Central nervous system stimulants
          (respiratory and cerebral
          stimulants, including sympa-
          thomimetic agents employed
          mainly as CNS stimulants);
          excluding nondrug dietaries for
          weight control):
3254124161             Amphetamines....................................  (D) (D) - (D) (D) (D) - (D)
3254124164             Anorexiants (except ampheta-
              mines)................................................ b/ 96,598 (D) (D) (D) b/ 52,014 (D) (D) (D)
3254124167             Other CNS stimulants..........................  1,325,258 (D) (D) (D) 1,090,078 1,088,376 b/    1,702 (D)
        Sedatives and hypnotics:
            Prescription:
3254124171                Barbiturates...................................... c/ 29,847 c/ 29,847 (X) (D) 46,533 46,533 (X) (D)
3254124174                Nonbarbiturates............................... b/ 257,029 b/ 257,029 (X) (D) b/ 330,225 b/     330,225 (X) (D)
            Nonprescription:
3254124177                 Sleep inducers.................................  48,483 (X) 48,483 - 67,315 (X) 67,315 -
3254124181                 Calming agents................................  (D) (X) (D) - (D) (X) (D) -
        Anesthetics (except urinary tract
          anesthetics and skin preparations
          used as antipruritics):   
3254124184             Local and topical.................................  (D) (D) (D) (D) 246,370 (D) (D) (D)
3254124187             General................................................  546,416 (D) (D) (D) r/ 617,589 (D) (D) (D)
2005 2004
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        Eye and ear preparations, 
          excluding anti-infectives, 
          corticoids and antibacterials
          and antiseptics:
3254124191             Mydriatics and miotics........................  (D) (D) - - (D) (D) - -
3254124193             Contact lens solutions.........................  574,614 - 574,614 (D) 569,412 - 569,412 (D)
3254124195             Other eye and ear preparations..........  1,299,512 (D) (D) (D) 1,163,086 (D) (D) -
3254124197         Other pharmaceutical prepara-
          tions acting on the central 
          nervous system and the sense
          organs, for human use.......................... a/ 2,550,248 (D) (D) (D) 3,259,175 3,072,540 186,635 163,269
3254127     Pharmaceutical preparations 
      acting on the cardiovascular 
      system, for human use.............................. a/ 10,245,714 (D) (D) 132,756 10,223,797 (D) (D) 143,377
3254127111         Anticoagulants........................................ a/ 785,826 (D) (D) (D) a/r/ 773,225 (D) (D) (D)
3254127116         Hemostatics.............................................  (D) (D) - - (D) (D) - -
3254127121         Digitalis preparations..............................  (D) (D) - (D) (D) (D) - (D)
        Hypotensives:  
3254127126             Rauwolfia-alkaloid preparations………  (D) (D) - - (D) (D) - -
3254127131             Beta receptor blocking agents............. a/ 191,518 (D) (D) (D) r/ 223,454 (D) (D) (D)
3254127136             Other hypotensives.............................  396,925 396,925 - (D) 420,317 420,317 - (D)
        Vasodilators:
3254127141             Coronary..............................................  (D) (D) - (D) (D) (D) - (D)
3254127146             Peripheral............................................  (D) (D) - - (D) (D) - -
3254127151             Antiarrythmics, such as
              propanolol and quinidine................. a/ 119,502 a/ 119,502 - (D) a/ 197,856 a/     197,856 - (D)
3254127156             Calcium channel blockers 
              such as isoptin, calan, pro-
              cardia, cardizem, adalat....................  415,283 415,283 - (D) 617,556 617,556 - (D)
3254127161             Ace inhibitors, such as vasotec,
               capoten, prinivil, and zestril………… b/ 805,295 b/ 805,295 - - b/ 961,740 b/     961,740 - (D)
3254127166         Other pharmaceutical prepara-
          tions, acting on the cardiovas-
          cular system, including
          vasopressors, and antiheparin
          agents, for human use………………………  5,484,630 (D) (D) 39,203 4,896,491 (D) (D) r/    34,918
325412A     Pharmaceutical preparations 
      acting on the respiratory system,
      for human use........................................... b/ 16,215,729 a/ 13,886,638 a/ 2,158,078 171,013 15,148,446 12,682,611 2,319,088 r/  146,747
325412A111        Antihistamines (except cold
         preparations and antiemetics)...............  1,585,700 (D) (D) (D) 2,123,801 (D) (D) (D)
325412A116        Bronchial dilators, including  
         antiasthmatics........................................ a/ 5,131,480 a/ 5,111,213 20,267 (D) 4,493,921 4,477,586 16,335 (D)
       Cough and cold preparations 
         (prescription):
           Cough preparations and 
             expectorants (containing
             antitussive or other ingredients
             intended primarily to treat 
             cough only):
325412A121                Narcotic............................................  (D) (D) (X) - (D) (D) (X) -
325412A126                Nonnarcotic......................................  34,249 34,249 (X) (D) r/ 33,821 r/  33,821 (X) (D)
          Cold preparations containing
            combinations of the following
            ingredients, (but not antitus-
            sive) nasal decongestant, anti-
            histamine, analgesic, bioflava-
            noid, or antibiotic):   
325412A131               Nasal decongestants..........................  (D) (D) (X) (D) (D) (D) (X) -
325412A136               Antihistamine cold
                preparations.................................... b/ 17,053 b/ 17,053 (X) - b/ 13,894 b/       13,894 (X) -
325412A141               Other prescription cold
                preparations....................................  2,492 2,492 (X) - 6,914 6,914 (X) -
325412A146           Cough and cold combinations   
            (prescription).......................................  69,845 69,845 (X) (D) 58,684 58,684 (X) (D)
          Cough and cold preparations 
            (nonprescription):
             Decongestants:
325412A151                  Nasal sprays...................................  102,600 (X) 102,600 - 99,268 (X) 99,268 -
325412A156                  Nose drops.....................................  (D) (X) (D) - (D) (X) (D) -
325412A161                  Other decongestants......................  (D) (X) (D) (D) 112,641 (X) 112,641 (D)
325412A166              Cough syrups..................................... b/ 631,499 (X) b/ 631,499 - 663,052 (X) 663,052 -
325412A171              Capsules and tablets.......................... a/ 459,089 (X) a/ 459,089 (D) 495,233 (X) 495,233 (D)
325412A176              Lozenges............................................  18,473 (X) 18,473 - 11,947 (X) 11,947 -
325412A181              Topical preparations..........................  (D) (X) (D) - (D) (X) (D) -
325412A186              Cough drops.......................................  (D) (X) (D) - (D) (X) (D) -
325412A191              Other nonprescription 
               cough and cold preparations…………  (D) (X) (D) (D) 171,780 (X) 171,780 (D)
325412A194              Beta agonists such as proventil
               and ventolin.....................................  (D) (D) (D) (D) 745,594 (D) (D) (D)
325412A197           Other pharmaceutical prep-
            arations acting on the 
            respiratory system, for human
            use.......................................................  5,710,791 5,701,949 8,842 a/ 14,711 5,782,720 5,773,705 9,015 5,631
325412 D      Pharmaceutical preparations    
       acting on the digestive or the
       genito-urinary systems, for
       human use................................................  16,775,884 a/ 15,036,526 a/ 981,572 757,786 15,251,818 13,773,555 (D) (D)
        Digestive system preparations: 
325412D111             Enzymes.............................................. a/ 106,497 a/ 95,270 11,227 (D) r/ 93,032 r/        82,168 10,864 (D)
325412D114             Antacids, including acid 
              neutralizing products with
              coating functions, but
              excluding effervescent
              salicylate products classified
              as analgesics..................................... b/ 507,059 (D) (D) (D) 658,985 (D) (D) (D)
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325412D117         Antidiarrheals..........................................  735,572 (D) (D) (D) 803,860 (D) (D) (D)
        Laxatives:
325412D121             Irritants...............................................  78,563 (D) (D) - 78,779 (D) (D) -
325412D124             Bulk producing....................................  (D) (D) (D) - (D) (D) (D) -
325412D127             Fecal softeners.................................... a/ 109,109 (D) (D) (D) a/r/ 40,901 r/          6,738 b/    34,163 (D)
325412D131             Emollients...........................................  (D) - (D) - (D) - (D) -
325412D134             Saline...................................................  (D) - (D) - 24,272 - 24,272 -
325412D137             Enema specialties................................  57,933 (D) (D) - 81,565 (D) (D) -
325412D141         Digestants...............................................  (D) (D) (D) (D) (D) (D) (D) (D)
325412D144         Bile therapy preparations, 
          including bile products, cho-
          leretics, and cholagogues......................  (D) (D) (D) - (D) (D) (D) -
325412D147         Antinauseants and motion 
          sickness remedies (antiemetics),
          including antihistaminic anti-
          emetic preparations..............................  547,214 (D) (D) (D) 294,600 292,653 1,947 (D)
325412D151         Lipotropics and cholesterol 
          reducers................................................  (D) (D) (D) (D) (D) (D) (D) (D)
325412D154         Diet aids containing local
          anesthetics such as benzocaine…………  15,134 (D) (D) (D) r/ 13,269 (D) (D) (D)
        Antispasmodics and anticho-
          cholinergics:
325412D157             Synthetics............................................  5,202 5,202 - - 5,647 5,647 - -
325412D161             Ataractic combinations.......................  (D) (D) - - (D) (D) - -
325412D164             Belladonna and derivatives.................  9,652 9,652 - (D) 11,938 11,938 - (D)
325412D167             H2 Blocking agents such as
              zantac, tagemet, carafate,
              and pepcid.........................................  1,191,533 (D) (D) - r/ 1,315,579 (D) (D) (D)
325412D171             Other antispasmodics and
              anticholinergics................................. b/ 30,557 (D) (D) - 40,422 (D) (D) -
325412D174         Other digestive system 
          preparations, including emetics...........  524,248 517,521 a/ 6,727 (D) 415,484 (D) (D) (D)
        Genito-urinary preparations:   
325412D177             Urinary antibacterials and
              antiseptics.........................................  35,748 (D) (D) - a/r/ 48,605 a/r/       43,570 c/      5,035 -
            Diuretics, excluding amino-
              phyllne, xanthine, and
              rauwolfia-diuretic combin-
              nations (see cardivascular
              preparations):
325412D181                 Thiazides and related agents..........  42,648 42,648 - - r/ 43,684 r/       43,684 - -
325412D184                 Other diuretics................................ a/ 100,236 (D) (D) (D) r/ 112,843 (D) (D) -
325412D187             Oxytocics.............................................  89,399 89,399 - - 75,175 75,175 - -
325412D191             Contraceptive agents 
              (except oral contraceptives)
              aerosols, jels, sponges, and
              creams...............................................  (D) (D) (D) - (D) (D) (D) -
325412D193             Premenstrual tension prep-
              arations.............................................  (D) - (D) - (D) - (D) -
325412D195             Vaginal cleaners..................................  67,376 (D) (D) - 54,224 (D) (D) -
325412D197         Other pharmaceutical prep-
          arations acting on the genito-
          urinary system, including
          urinary tract anesthetics, for
          human use……………………………………  1,348,293 1,339,917 8,376 (D) r/ 1,429,746 r/  1,420,483 9,263 (D)
325412G     Pharmaceutical preparations 
      acting on the skin, for human use………… b/ 3,245,247 (D) 1,778,933 (D) 3,283,003 (D) 1,627,736 (D)
        Dermatological preparations:
325412G111             Emollients and protectives,
              including burn remedies and
              ointment bases..................................  804,254 (D) (D) - 619,936 45,001 574,935 -
325412G116             Antipruritics and local
               anesthetic skin preparations…………  185,304 132,412 a/ 52,892 (D) 300,310 129,879 170,431 (D)
325412G121             Coal tar, sulfur and resorcinol
               preparations.....................................  (D) (D) (D) - 8,301 (D) (D) -
325412G126              Antiacne preparations........................  574,324 346,267 228,057 (D) r/ 605,286 394,322 210,964 (D)
325412G131              Antidandruff and anti-
               seborrheic preparations
               (except dandruff shampoos)............ b/ 32,115 (D) (D) - 43,856 (D) (D) -
325412G136             Other dermatological 
              preparations...................................... b/ 590,495 b/ 426,713 a/ 163,782 (D) 790,087 r/    627,967 r/   162,120 (D)
325412G141         Hemorrhoidal preparations..................... a/ 80,385 (D) (D) - 88,034 12,039 75,995 -
        External analgesics and counter-
          irritants:
325412G146             Ointments, jellies, pastes,
              creams, cerates, and salves…………… b/ 356,565 (D) (D) (D) 346,574 (D) (D) -
325412G151             Liquid, excluding rubbing
              alcohol, but including lini-
              ments................................................  22,730 - 22,730 - 20,109 - 20,109 -
325412G156             Rubbing alcohol..................................  (D) (D) (D) - a/ 29,909 (D) (D) -
325412G161             Other external analgesics and
              counterirritants.................................  32,037 (D) (D) - b/ 27,935 (D) (D) -
325412G166         Other pharmaceutical preparations
          acting on the skin, for human use……… c/ 438,096 c/ 339 b/ 86,413 (D) a/ 336,371 246,606 b/     89,765 (D)
325412L     Vitamin, nutrient, and hematinic 
      preparations, for human use..................... a/ 6,827,371 1,904,795 a/ 4,653,505 b/ 269,071 a/r/ 6,683,224 1,697,158 a/r/ 4,755,523 b/  230,543
        Vitamins:
325412L111            Multivitamins, plain and with
              minerals, (except B complex
              vitamins and fish liver oils)..............  2,584,435 b/ 37,533 2,546,902 b/ 68,507 2,649,302 b/      28,767 2,620,535 a/    54,730
325412L116            Pediatric vitamin preparations
             (drops, suspensions and chew-
             able tablets)........................................ b/ 144,858 (D) (D) c/ 940 b/ 162,654 (D) (D) 1,112
325412L121            Prenatal vitamin preparations……………  88,719 (D) (D) c/ 807 69,200 61,953 7,247 825
325412L126            B complex preparations.......................  264,998 18,540 246,458 a/ 5,309 r/ 259,996 23,944 r/    236,052 5,218
325412L131            Fluoride preparations...........................  (D) (D) (D) - r/ 4,040 (D) (D) (D)
325412L136            All other vitamin preparations............. b/ 636,945 39,114 a/ 597,831 c/ 68,591 r/ 643,343 r/      39,838 r/    603,505 64,292
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   Product Product description Pre- Pre-
      code scription Nonpre- Bulk ship- scription Nonpre- Bulk ship-
Total legend scription ments 1/ Total legend scription ments 1/
  
2005 2004
325412L141         Fish liver oils (cod, etc.)..........................  138,934 (D) (D) b/ 237 112,775 (D) (D) 196
325412L146         Nutrients, excluding therapeutic
          dietary foods and infant formulas……… a/ 316,110 70,329 245,781 a/ 92,929 a/ 346,757 67,898 a/    278,859 72,011
325412L151         Tonics and alteratives............................. c/ 29,351 - c/ 29,351 - 27,602 - 27,602 -
        Hematinics:
            With B12:
325412L156                 Oral.................................................. b/ 30,941 (D) (D) (D) 33,021 (D) (D) 41
325412L161                 Parenteral........................................  (D) (D) (D) - (D) (D) (D) -
            Other hematinics:
325412L166                 Oral..................................................  31,618 (D) (D) (D) 27,821 (D) (D) (D)
325412L171                 Parenteral........................................  (D) (D) - - (D) (D) - -
325412L176         Hospital solutions, including
           dextran, etc., but excluding
           biologicals such as blood plasma........  776,673 (D) (D) - r/ 806,669 (D) (D) -
325412L181         Other vitamin, nutrient, and
           hematinic preparations, for 
           human use............................................  1,476,779 765,028 711,751 28,942 r/ 1,276,328 548,605 r/    727,723 27,575
325412P     Pharmaceutical preparations 
      affecting parasitic and infective
      diseases, for human use............................ b/ 11,244,039 a/ 9,822,838 1,247,315 b/ 173,886 10,818,532 9,668,870 r/    934,462 215,200
       Anti-infective agents, excluding   
         cortcoid anti-infective combi-
         nations (see product code
         3254121015):   
325412P111            Amebicides and trichomonicides……… a/ 35,890 a/ 35,890 - - 33,225 33,225 - -
325412P114            Anthelmintics.......................................  1,191 (D) (D) - 1,030 (D) (D) -
           Systemic antibiotic preparations:
               Broad and medium spectrum
                 (single or in combinations
                 with other antibiotics):
325412P117                    Tetracyclines, including
                     chlortetracycline and
                     congeners................................... a/ 276,012 a/ 276,012 - - a/r/ 169,619 a/r/    169,619 - -
325412P121                    Cephalosporins, such as
                     cefamandolenafate and
                     dolenafate and cephalexin.........  1,217,525 1,217,525 - (D) 1,313,882 1,313,882 - (D)
325412P124                    Erythromycins, such as
                     erythromycin ethyl-
                     succinate and erythro-
                     mycin stearate............................  109,571 (D) (D) - r/ 62,000 r/       62,000 - -
                   Penicillins (single):
                       Semisynthetic penicillins,
                         such as amoxicillins,
                         and ampicillin:
325412P127                            Injectable..............................  206,645 206,645 - - 205,388 205,388 - -
325412P131                            Other forms..........................  (D) (D) - - r/ 502,063 r/     502,063 - -
                       Other penicillins (except
                         semisynthetic), such as
                         penicillin V and peni-
                         cillin G:
325412P134                            Injectable..............................  5,483 5,483 - - 2,794 2,794 - -
325412P137                            Other forms..........................  (D) (D) - - (D) (D) - -
325412P141                    Other broad and medium
                     spectrum antibiotics 
                     (except sulfa-antibiotic
                     combinations).............................  761,658 (D) (D) - r/ 808,215 (D) (D) -
325412P144                Antibiotics in combination
                 with sulfonamides..........................  66,841 66,841 - - (D) (D) - -
325412P147                Other systemic antibiotic 
                 preparations, including
                 narrow-spectrum antibiotics
                 and streptomycins……………………  (D) (D) - - a/ 115,077 a/     115,077 - (D)
325412P151            Topical antibiotic preparations............ b/ 394,860 (D) (D) - 303,681 (D) (D) -
           Tuberculostatic agents:
325412P154                Isoniazid (isonicotinic acid
                hydrazide) preparations.................. a/ 6,242 a/ 6,242 - - b/ 2,664 b/         2,664 - -
325412P157                Other antituberculars.......................  (D) (D) - - (D) (D) - -
325412P161             Antimalarials (plasmodicides)............. a/ 32,486 a/ 32,486 - (D) r/ 33,893 r/       33,893 - (D)
325412P164             Sulfonamides (except antibiotic
              sulfonamide combinations)............... a/ 25,074 a/ 25,074 - - 25,997 25,997 - -
325412P167             Antifungal preparations......................  1,233,903 1,056,645 177,258 - 1,220,509 (D) (D) -
325412P171             Antivirals, systemic, such as
              zovirax, and retrovir…………………… b/ 4,010,762 (D) (D) 78,273 r/ 3,639,945 (D) (D) 72,727
325412P174             Other anti-infective agents..................  (D) (D) (D) (D) (D) (D) (D) (D)
        Antibacterials and antiseptics:
325412P177             General................................................  (D) (D) (D) 7,192 390,854 (D) (D) 6,837
325412P181             Mouth and throat preparations...........  (D) 9,828 (D) (D) (D) 9,045 (D) (D)
325412P184         Other pharmaceutical preparations
          affecting parasitic and infective
          diseases, for human use........................  428,647 410,603 18,044 (D) 420,398 401,821 18,577 (D)
325412T     Pharmaceutical preparations, for
      veterinary use........................................... a/ 3,361,922 a/ 2,310,171 a/ 930,989 a/ 120,762 a/r/ 2,652,898 b/r/  1,661,172 916,404 75,322
325412T111        Anesthetics...............................................  60,795 60,795 - - 48,635 48,635 - -
325412T116        Anthelmintics........................................... b/ 245,607 (D) (D) (D) 269,560 221,737 47,823 (D)
       Antibiotics:
325412T121            Tetracyclines........................................  26,601 (D) (D) (D) 25,378 (D) (D) -
325412T126            Penicillins.............................................  39,131 26,947 12,184 - 31,270 18,813 12,457 -
325412T131            Other antibiotics..................................  788,905 745,907 42,998 (D) 561,394 444,682 116,712 (D)
325412T136         Antiseptics, wound dressings
          and fungicides.......................................  84,720 54,559 a/ 30,161 (D) 98,029 (D) (D) (D)
325412T141         Hematinics..............................................  (D) - (D) - (D) - (D) -
325412T146         Hemostatics.............................................  - - - - - - - -
        Hormones:
325412T151             Insulin preparations............................  (D) (D) - - (D) (D) - -
325412T156             ACTH (corticotropin) prep-
              arations.............................................  (D) (D) - - (D) (D) - -
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[In thousands of dollars]
 
   Product Product description Pre- Pre-
      code scription Nonpre- Bulk ship- scription Nonpre- Bulk ship-
Total legend scription ments 1/ Total legend scription ments 1/
  
2005 2004
325412T161             Other hormone preparations..............  194,502 (D) (D) - 153,106 (D) (D) -
325412T166         Intravenous solutions and 
         electrolytes.............................................  17,604 (D) (D) (D) 13,140 (D) (D) (D)
325412T171         Nitrofurans..............................................  (D) - (D) (D) (D) - (D) (D)
325412T176         Nutrients and tonics................................  (D) (D) b/ 1,450 (D) (D) (D) b/       1,266 (D)
325412T181         Parasiticides, external............................. c/ 196,886 (D) (D) (D) b/ 157,511 (D) (D) (D)
325412T186         Sulfonamides...........................................  10,414 (D) (D) - 9,217 (D) (D) -
325412T191         Tranquilizers and ataractics...................  9,235 (D) (D) - 31,206 (D) (D) -
325412T194         Vitamins and minerals............................ b/ 199,508 (D) (D) (D) 163,296 3,828 159,468 (D)
325412T197         Other pharmaceutical preparations,
          for veterinary use.................................. a/ 1,345,162 a/ 975,556 369,606 (D) r/ 999,764 r/     662,195 337,569 (D)
      -  Represents zero.     D  Withheld to avoid disclosing data for individual companies.      r/Revised 5 percent from previously published data.      X  Not applicable.
 
      1/Data for "Bulk shipments" are excluded from all horizontal ten-digit product detail totals; however, these data are included in all seven-digit product classes and six-digit industry
level totals.  Since bulk shipments are typically reported by a small number of producers, and often must be suppressed, inclusion of bulk shipments in all horizontal totals would require
the suppression of additional detail.
      Note:  Percent of estimation of each item is indicated as follows:  a/10 to 25 percent of this item is estimated.     b/26 to 50 percent of this item is estimated.     c/Over 50 percent
of this item is estimated.
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Table 3.  Domestic Value of Shipments, Exports, Imports, and Apparent Consumption of Pharmaceutical Preparations, Except Biologicals:  2005 and 2004
[Thousands of dollars]
Manu- Percent Percent
facturers' Exports of exports Imports for Apparent imports
Product Product description shipments domestic to manu- consump- consump- to apparent
code (value merchan- facturers' tion 2/ tion 3/ consumption
f.o.b. plant) dise 1/ shipments (value) (value) (value)
 
2005  
Pharmaceutical preparations......................................................... 116,301,385 10,181,450 8.8 27,058,021 133,177,956 20.3
 
3254121100     Pharmaceutical preparations affecting neoplasms, endo-  
      crine system, and metabolic diseases, for human use............ 23,341,374 2,898,772 12.4 4,986,873 25,429,475 19.6
 
3254124100     Pharmaceutical preparations acting on the central nervous  
      system and sense organs, for human use...............................  25,044,005 2,217,027 8.9 4,643,207 27,470,185 16.9
 
3254127100     Pharmaceutical preparations acting on the cardiovascular  
      system, for human use............................................................  10,245,714 1,295,231 12.6 8,993,166 17,943,649 50.1
 
325412A100     Pharmaceutical preparations acting on the respiratory  
      system, for human use............................................................  16,215,729 458,486 2.8 1,743,603 17,500,846 10.0
 
325412D100     Pharmaceutical preparations acting on the digestive or  
      genito-urinary system, for human use....................................  16,775,884 347,823 2.1 2,127,985 18,556,046 11.5
 
325412G100     Pharmaceutical preparations acting on the skin, for human  
      use...........................................................................................  3,245,347 99,119 3.1 387,204 3,533,432 11.0
 
325412L100     Vitamin, nutrient, and hematinic preparations, for human  
      use...........................................................................................  6,827,371 343,239 5.0 400,727 6,884,859 5.8
 
325412P100     Pharmaceutical preparations affecting parasitic and  
      infective diseases, for human use...........................................  11,244,039 2,269,143 20.2 3,292,511 12,267,407 26.8
 




Pharmaceutical preparations......................................................... 109,851,975 9,561,187 8.7 24,760,246 125,051,034 19.8
 
3254121100     Pharmaceutical preparations affecting neoplasms, endo-  
      crine system, and metabolic diseases, for human use............ 20,789,103 2,954,777 14.2 4,066,471 21,900,797 18.6
3254124100     Pharmaceutical preparations acting on the central nervous
      system and sense organs, for human use...............................  25,001,154 2,406,074 9.6 5,510,867 28,105,947 19.6
3254127100     Pharmaceutical preparations acting on the cardiovascular
      system, for human use............................................................  10,223,797 895,710 8.8 7,303,533 16,631,620 43.9
325412A100     Pharmaceutical preparations acting on the respiratory
      system, for human use...................................................…… 15,148,446 584,095 3.9 2,058,401 16,622,752 12.4
325412D100     Pharmaceutical preparations acting on the digestive or
      genito-urinary system, for human use............................…… 15,251,818 293,906 1.9 2,130,589 17,088,501 12.5
325412G100     Pharmaceutical preparations acting on the skin, for human
      use...........................................................................................  3,283,003 71,111 2.2 404,918 3,616,810 11.2
 
325412L100     Vitamin, nutrient, and hematinic preparations, for human
      use........................................................................................... r/ 6,683,224 345,681 5.2 126,420 6,463,963 2.0
325412P100     Pharmaceutical preparations affecting parasitic and
      infective diseases, for human use...........................................  10,818,532 1,764,062 16.3 2,625,849 11,680,319 22.5
325412T100     Pharmaceutical preparations for veterinary use....................... r/ 2,652,898 245,771 9.3 533,198 2,940,325 18.1
      r/Revised by 5 percent or more from previously published data.
      1/Source:  Census Bureau report EM 545, U.S. Exports.
      2/Source:  Census Bureau report IM 145, U.S. Imports for Consumption.
      3/Apparent consumption represents new domestic supply and is derived by substracting exports from the total of manufacturers' shipments plus imports.
      Note:  Revisions to the 2004 data for imports and exports are due to an error where code changes were not implemented correctly. 
Table 4.  Comparison of North American Industry Classification System (NAICS)-Based Product Codes with Schedule B
               Export Codes, and HTSUSA Import Codes:  2005
Product   
code Product description               Export code 1/              Import code 2/
3254121100 Pharmaceutical preparations affecting
  neoplasms, endocrine system, and
  metabolic disease............................................  3003.31.0000, 3003.39.0000, 3003.31.0000, 3003.39.1000,
3003.40.0000, 3004.31.0000, 3003.39.5000, 3003.40.0000,
3004.32.0000, 3004.39.0050, 3004.31.0000, 3004.32.0000,
3004.90.9115 3004.39.0050, 3004.90.9115
3254124100 Pharmaceutical preparations acting on
  central nervous system and sense
  organs..............................................................  3004.40.0020, 3004.40.0030, 3004.40.0020, 3004.40.0030,
3004.40.0040, 3004.90.9125, 3004.40.0040, 3004.90.9122,
3004.90.9130, 3004.90.9135, 3004.90.9126, 3004.90.9128,
3004.90.9140 3004.90.9130, 3004.90.9135,
3004.90.9140
3254127100 Pharmaceutical preparations acting on 
  cardiovascular system..................................... 3004.40.0010, 3004.90.9120 3004.40.0010, 3004.90.9120
325412A100 Pharmaceutical preparations acting on
  respiratory system..........................................  3004.40.0060, 3004.90.9175, 3004.40.0060, 3004.90.9175,
3004.90.9180, 3004.90.9185 3004.90.9180, 3004.90.9185
325412D100 Pharmaceutical preparations acting on
  digestive or genitro-urinary system................  3004.90.9150, 3004.90.9155, 3004.90.9150, 3004.90.9155,
 3004.90.9160, 3004.90.9165, 3004.90.9160, 3004.90.9165,
3004.90.9170, 3006.60.0000 3004.90.9170, 3006.60.0000
325412G100 Pharmaceutical preparations acting on
  skin..................................................................  3004.40.0050, 3004.90.9145 3004.40.0050, 3004.90.9145
325412L100 Vitamin, nutrient and hematinic
  preparations....................................................  3004.50.4500, 3004.50.5010, 3004.50.1000, 3004.50.2000,
 3004.50.5020, 3004.50.5030, 3004.50.3000, 3004.50.4000,
3004.50.5040 3004.50.5010, 3004.50.5020,
3004.50.5030, 3004.50.5040
325412P100 Pharmaceutical preparations affecting
  parasitic and infective disease........................  3003.10.0000, 3003.20.0000, 3003.10.0000, 3003.20.0000,
3004.10.1020, 3004.10.1045, 3004.10.1020, 3004.10.1045,
3004.10.5045, 3004.10.5060, 3004.10.5045, 3004.10.5060,
3004.20.0020, 3004.20.0030, 3004.20.0020, 3004.20.0030,
3004.20.0060, 3004.90.1000, 3004.20.0060, 3004.90.1000,
3004.90.9105, 3004.90.9110 3004.90.9105, 3004.90.9110
325412T100 Pharmaceutical preparations, for
  veterinary use.................................................. 3004.10.1010, 3004.10.5010, 3004.10.1010, 3004.10.5010,
3004.20.0010, 3004.39.0010, 3004.20.0010, 3004.39.0010,
3004.40.0005, 3004.50.5005, 3004.40.0005, 3004.50.5005,
3004.90.9103 3004.90.9103
      1/Source:  2005 edition, Harmonized System-based Schedule B, Statistical Classification of Domestic and Foreign
Commodities Exported from the United States.    
      2/Source:  Harmonized tariff Schedule of the United States, Annotated (2005).
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Appendix.  
General CIR Survey Information, Explanation of General Terms
and Historical Note
GENERAL
The CIR program has been providing monthly,
quarterly, and annual measures of industrial activity for
many years. Since 1904, with its cotton and fats and oils
surveys, the CIR program has formed an essential part
of an integrated statistical system involving the quin-
quennial economic census, manufacturing sector, and
the annual survey of manufactures. The CIR surveys,
however, provide current statistics at a more detailed
product level than either of the other two statistical
programs.
The primary objective of the CIR program is to
produce timely, accurate data on production and
shipments of selected products. The data are used to
satisfy economic policy needs and for market analysis,
forecasting, and decision making in the private sector.
The product-level data generated by these surveys are
used extensively by individual firms, trade associations,
and market analysts in planning or recommending
marketing and legislative strategies, particularly if their
industry is significantly affected by foreign trade.
Although production and shipments information are the
two most common data items collected, the CIR
program collects other measures also such as
inventories, orders, and consumption. These surveys
measure manufacturing activity in important commodity
areas such as textiles and apparel, chemicals, primary
metals, computer and electronic components, industrial
equipment, aerospace equipment, and consumer
goods.
The CIR program uses a unified data collection,
processing, and publication system. The U.S. Census
Bureau updates the survey panels for most reports
annually and reconciles the estimates to the results of
the broader-based annual survey of manufactures and
the economic census, manufacturing sector. The manu-
facturing sector provides a complete list of all
producers of the products covered by the CIR program
and serves as the primary source for CIR sampling.
Where a small number of producers exist, CIR surveys
cover all known producers of a product. However, when
the number of producers is too large, cutoff and
random sampling techniques are used. Surveys are
continually reviewed and modified to provide the most
up-to-date information on products produced. The CIR
program includes a group of mandatory and voluntary
surveys.  Typically the monthly and quarterly surveys are
conducted on a voluntary basis. Those companies that
choose not to respond to the voluntary surveys are
required to submit a mandatory annual counterpart
corresponding to the more frequent survey.
NORTH AMERICAN INDUSTRY CLASSIFICATION
SYSTEM (NAICS), 1997 
The adoption of the North American Industry
Classification System (NAICS) in the 1997 Economic
Census has had a major impact on the comparability of
current and historic data. Approximately half of the
industries in the manufacturing sector of NAICS do not
have comparable industries in the Standard Industrial
Classification (SIC) system that was used in the past.
While most of the change affecting the
manufacturing sector was change within the sector,
some industries left manufacturing and others came into
manufacturing. Prominent among those that left
manufacturing are logging and portions of publishing.
Prominent among the industries that came into the
manufacturing sector are bakeries, candy stores where
candy is made on the premises, custom tailors, makers
of custom draperies, and tire retreading. The net effect
of the classification changes are such that if the 1997
value of shipments data for all manufacturers were
tabulated on an SIC basis, it would be approximately 3
percent higher.







48-49 Transportation and Warehousing
51 Information
52 Finance and Insurance
53 Real Estate and Rental and Leasing
54 Professional, Scientific, and Technical Services
55 Management of Companies and Enterprises
56 Administrative and Support and Waste Management
and Remediation Services
61 Educational Services
62 Health Care and Social Assistance
71 Arts, Entertainment, and Recreation
72 Accommodation and Food Services
81 Other Services (except Public Administration)
(Not listed above are the Agriculture, Forestry,
Fishing, and Hunting sector (NAICS 11), partially covered
by the census of agriculture conducted by the U.S.
Department of Agriculture, and the Public
Administration sector (NAICS 92), covered by the census
of governments conducted by the Census Bureau.)
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The 20 NAICS sectors are subdivided into 96
subsectors (three-digit codes), 313 industry groups
(four-digit codes), and, as implemented in the United
States, 1170 industries (five- and six-digit codes).
FUNDING
The Census Bureau funds most of the surveys.
However, a number of surveys are paid for either fully
or partially by other Federal Government agencies or
private trade associations. A few surveys are mandated,
but all are authorized by Title 13 of the United States
Code.
RELIABILITY OF DATA
Survey error may result from several sources
including the inability to obtain information about all
cases in the survey, response errors, definitional
difficulties, differences in the interpretation of
questions, mistakes in recording or coding the reported
data, and other errors of collection, response,
coverage, and estimation. These nonsampling errors
also occur in complete censuses. Although no direct
measurement of the biases due to these nonsampling
errors has been obtained, precautionary steps were
taken in all phases of the collection, processing, and
tabulation of the data in an effort to minimize their
influence.
A major source of bias in the published estimates is
the imputing of data for nonrespondents, for late
reporters, and for data that fail logic edits. Missing
figures are imputed based on period-to-period
movements shown by reporting firms. A figure is
considered to be an impute if the value was not directly
reported on the questionnaire, directly derived from
other reported items, directly available from
supplemental sources, or obtained from the respondent
during the analytical review phase. Imputation generally
is limited to a maximum of 10 percent for any one data
cell. Figures with imputation rates greater than 10
percent are suppressed or footnoted. The imputation
rate is not an explicit indicator of the potential error in
published figures due to nonresponse, because the
actual yearly movements for nonrespondents may or
may not closely agree with the imputed movements.
The range of difference between the actual and
imputed figures is assumed to be small. The degree of
uncertainty regarding the accuracy of the published
data increases as the percentage of imputation
increases. Figures with imputation rates above 10
percent should be used with caution.
DATA REVISIONS
Statistics for previous years may be revised as the
result of corrected figures from respondents, late
reports for which imputations were originally made, or
other corrections. Data that have been revised by more
than 5 percent from previously published data are
indicated by footnotes.
DISCLOSURE
The Census Bureau collects the CIR data under the
authority of Title 13, United States Code, which
specifies that the information can only be used for
statistical purposes and cannot be published or released
in any manner that would identify a person, household,
or establishment.  "D" indicates that data in the cell have
been suppressed to avoid disclosure of information
pertaining to individual companies.
EXPLANATION OF GENERAL TERMS
Capacity. The maximum quantity of a product that can
be produced in a plant in 1 day if operating for 24
hours. Includes the capacity of idle plants until the plant
is reported to be destroyed, dismantled, or abandoned.
Consumption.  Materials used in producing or
processing a product or otherwise removing the
product from the inventory.
Exports.  Includes all types of products shipped to
foreign countries, or to agents or exporters for
reshipment to foreign countries.
Gross shipments. The quantity or value of physical
shipments from domestic establishments of all products
sold, transferred to other establishments of the same
company, or shipped on consignment, whether for
domestic or export sale or use. Shipments of products
purchased for resale are omitted. Shipments of
products made under toll arrangements are included.
Interplant transfers.  Shipments to other domestic
plants within a company for further assembly,
fabrication, or manufacture.
Inventories.  The quantity or value of finished goods,
work in progress, and materials on hand.
Machinery in place. The number of machines of a
particular type in place as of a particular date whether
the machinery was used for production, prototype, or
sampling, or was idle. Machinery in place includes all
machinery set up in operating positions.
Net receipts.  Derived by subtracting the materials held
at the end of the previous month from the sum of
materials used during the current month.
Production.  The total volume of products produced,
including: products sold; products transferred or added
to inventory after adjustments for breakage, shrinkage,
and obsolescence, plus any other inventory adjustment;
and products that undergo further manufacture at the
same establishment.  
Quantities produced and consumed. Quantities of
each type of product produced by a company for
internal consumption within that same company.
Current Industrial Reports A-3
Quantity and value of new orders.  The sales value
of orders received during the current reporting period
for products and services to be delivered immediately
or at some future date. Also represents the net sales
value of contract change documents that increase or
decrease the sales value of the orders to which they are 
related, when the parties concerned are in substantial
agreement as to the amount involved.  Included as
orders are only those that are supported by binding
legal documents such as signed contracts or letter
contracts.
Quantity and value of shipments.  The figures on
quantity and value of shipments represent physical
shipments of all products sold, transferred to other
establishments of the same company, or shipped on
consignment, whether for domestic or export sale. The
value represents the net sales price, f.o.b. plant, to the
customer or branch to which the products are shipped,
net of discounts, allowances, freight charges, and
returns. Shipments to a company's own branches are
assigned the same value as comparable appropriate
allocation of company overhead and profit. Products
bought and resold without further manufacture are
excluded.
Stocks. Total quantity of ending finished inventory.
Unfilled orders (backlog). Calculated by adding net
new orders and subtracting net sales from the backlog
at the end of the preceding year.
HISTORICAL NOTE
Data on pharmaceutical preparations, except
biologicals, have been collected by the Census Bureau
since 1962.  Historical data may be obtained from
Current Industrial Reports available at your local Federal
Depository Library.
